Clene vs Serina Therapeutics
CLNN and SER side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLNN and SER compare
Clene is the larger company, worth 1.5 times as much as Serina Therapeutics ($53.9M against $36.3M).
Serina Therapeutics scores higher on the StockData Score (2 against 1 for Clene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLNN | SER |
|---|---|---|
| Size and price | ||
| Market cap | $53.9M | $36.3M |
| Share price | $4.20 | $1.43 |
| Change, 1 year | −58.4% | −63.4% |
| Change, 5 years | −95.8% | 81.0% |
| Beta (5Y) | 0.80 | −1.09 |
| Employees | 79 | 16 |
| StockData Score | ||
| Total score | 1 | 2 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 226× | – |
| FCF yield | – | −58.4% |
| Growth | ||
| Revenue growth (TTM) | 11.2% | – |
| Revenue growth, 5Y average | −0.59% (better) | −18.5% |
| Profitability | ||
| Gross margin | 68.5% | – |
| Operating margin | −8929% | – |
| Net margin | −11271% | – |
| Return on equity | – | −1175% |
| Financial health | ||
| Interest coverage | −7.3× | – |
| Current ratio | 0.85 | 6.65 (better) |
| Altman Z-score | −23.01 | −0.10 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 24.8% | 5.5% |
| Held by insiders | 45.9% | 49.7% |
| Insider net buying, 12 months | −$5.6M | −$232K (better) |
| Short interest, % of float | 6.0% | 0.37% |
Go deeper
- CLNN stock overview
- CLNN income statement
- CLNN valuation and score
- SER stock overview
- SER income statement
- SER valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.